Dr Angela Devine

Senior research officer

Qualifications:

PhD, The Open University, 2018; Master of Science, London School of Hygiene and Tropical Medicine, 2008; Bachelor of Science, University of Evansville, 2006

Approved level of HDR supervision at Charles Darwin University:

Associate for PhD

Location:

Melbourne

Biography:

Angela Devine is a health economist with 10 years of experience in the economic evaluation and costs related to the management of infectious diseases. Dr Devine’s current research is focused on the cost-effectiveness of options for the management of vivax malaria. In particular, Dr. Devine investigates options for improving the safety and effectiveness of radical cure in a variety of geographical and epidemiological settings.

Additional projects in global health extend from malaria to HIV, tuberculosis, hepatitis B, antimicrobial resistance, dengue. Methodological research interests include the joint costs and consequences of co-infections, the valuation of productivity losses in low and middle income countries, and the development of online tools to address policy decisions. Available online tools can be found here, here, and here.

In addition to her role at Menzies, Dr Devine is a lecturer at Charles Darwin University and holds an honorary position at The University of Melbourne, where she is part of the qMalaria team in the Centre for Epidemiology and Biostatistics Research and the Health Economics Unit. 

Her ORCID profile can be found here.

Dr Angela Devine
Email
Research Themes
  1. Global costs of Plasmodium vivax malaria estimated for the first time.

    Global costs of Plasmodium vivax malaria estimated for the first time.

    Date

    A new study published in the open-access journal PLOS Medicine by Dr. Angela Devine at Menzies School of Health Research in Australia, and colleagues estimate the global economic burden of P. vivax for the first time using country-level data.

  2. First study to estimate the global costs due to vivax malaria

    First study to estimate the global costs due to vivax malaria

    Date

    The global cost of vivax malaria infections could be reduced substantially if radical cure is used more effectively, a new paper has found.

  3. MEDIA RELEASE | First study to estimate the global costs due to vivax malaria

    MEDIA RELEASE | First study to estimate the global costs due to vivax malaria

    Date

    The global cost of vivax malaria infections could be reduced substantially if radical cure is used more effectively, a new paper has found.

  4. New study shows faster way to cure vivax malaria

    New study shows faster way to cure vivax malaria

    Date

    A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated.

  5. 7th International Conference on Plasmodium vivax Research | Final Report

    7th International Conference on Plasmodium vivax Research | Final Report

    Date

    MESA Correspondents bring you cutting-edge coverage from the 7th International Conference on Plasmodium vivax Research (ICPVR 2019).

  6. Coverage from the 7th International Conference on Plasmodium vivax Research

    Coverage from the 7th International Conference on Plasmodium vivax Research

    Date

    Wrapping up the 7th International Conference on Plasmodium vivax Research, day three focused on the topics of P. vivax drugs and approaches for P. vivax elimination.

  1. Devine, A., Howes, R. E., Price, D. J., Moore, K. A., Ley, B., Simpson, J. A., Dittrich, S. & Price, R. N. (2020). Cost-Effectiveness Analysis of Sex-Stratified Plasmodium vivax Treatment Strategies Using Available G6PD Diagnostics to Accelerate Access to Radical Cure. The American Journal of Tropical Medicine and Hygiene, 103(1), 394-403. https://doi.org/10.4269/ajtmh.19-0943.
  2. Devine, A., Pasaribu, A. P., Teferi, T., Pham, H. T., Awab, G. R., Contantia, F., Nguyen, T.N., Ngo, V.T., Tran, T.H., Hailu, A., Gilchrist, K., Green, J.A., Koh, G.C.K.W., Thriemer, K., Taylor, W.R.J., Day, N.P.J., Price, R.N. & Lubell, Y. (2019). Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. Bulletin of the World Health Organisation, 97(12), 828-836. https://doi.org/10.2471/blt.18.226688. 
  3. Taylor, W.R.J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N.H., Cheah, P.Y., Dong, L.T., Dhorda, M., Degaga, T.S., Devine, A., Ekawati, L.L., Fahmi, F., Hailu, A., Hasanzai, M.A., Hienm T.T., Khu, H., Ley, B., Lubell, Y., Marfurt, J., Mohammad, H., Moore, K.A., Naddim, M.N., Pasaribu, A.P., Pasaribu, S., Promnarate, C. . . Price, R.N. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. The Lancet, 394(10202), 929-938. https://doi.org/10.1016/s0140-6736(19)31285-1.
  4. Devine, A., Kenangalem, E., Burdam, F.H., Anstey, N.M., Poespoprodjo, J.R., Price, R.N. & Yeung, S. (2018). Treatment-seeking behavior after the Implementation of a unified policy of Dihydroartemisinin-Piperaquine for the treatment of uncomplicated malaria in Papua, Indonesia. The American Journal of Tropical Medicine and Hygiene, 98(2), 543-550. https://doi.org/10.4269/ajtmh.17-0680.
  5. Devine, A., Parmiter, M., Chu, C.S., Bancone, G., Nosten, F., Price, R.N., Lubell, Y. & Yeung, S. (2017). Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. PLoS Neglected Tropical Diseases, 11(5), e0005602. https://doi.org/10.1371/journal.pntd.0005602.
  6. Drake, T.L., Lubell, Y., Kyaw, S.S., Devine, A., Kyaw, M.P., Day, N.P.J., Smithius, F.M. & White, L.J. (2017). Geographic resource allocation based on cost effectiveness: An application to malaria policy. Appl Health Econ Health Policy, 15(3), 299-306. https://doi.org/10.1007/s40258-017-0305-2.
  7. Devine, A., Harvey, R., Min, A.M., Gilder, M.E.T., Paw, M.K., Kang, J., Watts, I., Hanboonkunupakarn, B., Nosten, F. & McGreardy, R. (2017). Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Infectious Diseases, 17(1), 552. https://doi.org/10.1186/s12879-017-2660-x.
  8. Drake, T. L., Devine, A., Yeung, S., Day, N.P., White, L.J. & Lubell, Y. (2016). Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review. Health Economics, 25(Supplement 1), 124-139. https://doi.org/10.1002/hec.3303.
  9. Devine, A., Taylor, S.J., Spencer, A., Diaz-Ordaz, K., Eldridge, S. & Underwood, M. (2014). The agreement between proxy and self-completed EQ-5D for care home residents was better for index scores than individual domains. Journal of Clinical Epidemiology, 67(9), 1035-1043. https://doi.org/10.1016/j.jclinepi.2014.04.005.
  10. Devine, A., Spencer, A., Eldridge, S., Norman, R. & Feder, G. (2012). Cost-effectiveness of identification and referral to improve safety (IRIS), a domestic violence training and support programme for primary care: a modelling study based on a randomised controlled trial. BMJ Open, 2(3), pii: e001008. http://dx.doi.org/10.1136/bmjopen-2012-001008.